Abstract
data suggests higher immunogenicity rates for these drugs (19). Patients treated with IFX and ADL can 112 be stratified based on the characteristics of the reaction towards the treatment. Primary non-responders 113 develop an immediate ADA response following infusion while secondary non-responders were reported 114 to develop ADA within 12 months of the initiation of treatment (20) . 115 116 Historically, studies reporting on the response following mAb administration and ADA prevalence have 117 been inconsistent due, in part, to the various assay formats used to monitor immunogenicity in clinical 118 trials (21, 22) . Each of the available formats has its limitations that can reduce its utility in clinical and 119 research settings and complicate interpretation of the data. Some assays have poor dynamic range and 120 may generate false-negative results because of interfering interaction with active drug or false-positive 121 results due to other antibodies such as rheumatoid factor (23). The pros and cons of the available assays 122 for the detection of ADA were previously elaborated and the formation of ADA following treatment 123 with IFX, ADL, and other TNFα antagonists including newly developed biosimilars were extensively 124 studied and reviewed elsewhere (9, (24) (25) (26) (27) . 125
126
Notwithstanding the effort invested in understanding the reasons for mAb immunogenicity and strategies 127 to increase their efficacy, little is known about the molecular mechanism that governs the formation of 128 ADA following treatment of mAbs. 129
130
In this study we investigated the molecular landscape of ADA following treatment with 131 TNF antagonists. First, we developed a simple accurate bio-immunoassay to quantify ADA in patient 132 sera. We further modified the bio-immunoassay to evaluate the neutralization capacity of the ADA. 133
Next, we aimed to profile the immune response following mAb administration. We utilized flow 134 cytometry to determine the frequency of B cells in the circulation to determine if the immune response 135 is a vaccine like response with similar dynamics. Lastly, we used Next Generation Sequencing (NGS) 136 and high-resolution shotgun tandem mass spectrometry (LC-MS/MS) to elucidate the molecular 137 composition of the generated ADA. 138
Using our developed bio-immunoassay we found that the ADA levels in serums from 55 patients ranges 139 between 2.7 to 1268.5g/ml. The modified bio-immunoassay enabled to differentiate between patients 140 that have high and low neutralization capacity. More interestingly, we found that patients with a high 141 neutralization capacity show a strong bias in the / light chain ratio thus, our data suggests that there 142 is a preferential usage of  light chains by ntADA. 143 We chose an IBD patient treated with IFX with high ADA levels and neutralization capacity to elucidate 144 the nature of the immune response following drug administration. We found that 10 days (D10) 145 following IFX infusion there is a 16 fold and approximately 4 fold increase in the frequency of 146 plasmablast (PB) and memory B cells (mBC) respectively, compared to the pre-infusion time point (D0). 
Results

162
Production of mAb-F(ab')2 to be used in the immunoassay 163
To investigate the molecular landscape of ADA following mAb administration we first aimed to 164 develop an accurate, sensitive, robust bio-immunoassay to determine ADA levels in sera. The 165 working hypothesis was that anti-idiotypic antibodies dominate the neutralizing ADA compartment 166 (26, 28) thus, the developed immunoassay was based on the drugs' F(ab')2 portion to be used as the 167 antigen (i.e. coating agent). 168 169 To achieve this, we used the immunoglobulin G (IgG)-cleaving enzyme (IdeS), a cysteine 170 proteinase enzyme that proteolytically cleaves immunoglobulins below the hinge region (29) (Fig.  171 1A). IFX was digested using IdeS by incubating 10 mg of clinical grade mAb with IdeS to reach 172 near complete digestion. Next, IFX-F(ab')2 was purified from Fc regions and undigested full IFX 173 by consecutive affinity chromatography steps comprising protein A and kappa-select columns. 174
175
Recovered IFX-F(ab')2 purity was evaluated by SDS-PAGE and ELISA to ensure that the IFX-176 F(ab')2 exhibits no traces of IFX-Fc/undigested IFX that will contribute to the background level 177 when using anti-Fc HRP conjugate at the detection phase (Fig. 1B, C) . Recovered IFX-F(ab')2 178 samples were found to be highly pure with basal signal levels similar to the signal observed in the 179 control samples (Fig. 1C) . The produced IFX-F(ab')2 was tested for functionality by ELISA with 180
TNFα as the coating agent and was found to show similar functionality as observed with intact IFX 181 (Fig. 1D) . ADL was subjected to the same preparative pipeline and demonstrated similar results 182 (Fig. S1) . 183
184
ADA Standard curve 185
Quantification of total ADA in serum requires a standard reference thus, we generated a standard 186 ADA pool that facilitates the quantification of ADA levels in sera of patient treated with IFX. ADA 187 were pooled from several serum samples collected from patients treated with IFX and purified by 188 consecutive affinity chromatography steps comprising protein G and a custom-made IFX-F(ab')2 189 affinity columns. We confirmed the affinity enrichment of ADA by applying the affinity 190 chromatography elution fraction to ELISA with IFX-F(ab')2 as the antigen (Fig. S2A) . The purity 191 and concentration of the purified ADA was determined by SDS-PAGE (Fig. S2B ) and nanodrop. 192
Moreover, we evaluated the effect of serum on ADA detection by spiking-in varying concentrations 193 of ADA in a negative control serum and found that serum does not affect the detection of ADA 194 (Fig. S2C) . 195
196
Quantitative measurement of ADA in serum 197
ADA detection is technically challenging as both the analyte and antigen are antibodies which may 198 result in the inability to differentiate between the mAb and ADA. To overcome this challenge, many 199 assays were previously developed (9). One of these immunoassays is the anti-human  chain 200 (AHLC) immunoassay that is used in clinical setups for monitoring the formation of ADA (28, 30) . 201
The principle of this assay is to detect ADA comprising  light chain, thus avoiding cross reactivity 202 with the drug that comprises the  light chain ( Fig. 2A) . ADA in serum and to provide a solution for detecting ADA that have kappa light chains. Thus, we 207 developed a new bio-immunoassay based on the F(ab')2 portion of the mAb. The bio-immunoassay 208 setup is described in Fig. 2B and is based on mAb-F(ab')2 as the coating antigen and anti-Fc HRP 209 conjugate used as the detection antibody. Each of the experimental setups to test ADA in serum 210 included an ADA negative serum as a control and ADA standard for the quantitation of total ADA. 211
First, we applied the newly developed bio-immunoassay on two types of sera, negative and positive 212 for ADA as determined by the AHLC assay (AHLC (-) and AHLC (+) , respectively). As shown in 213 Figure 2C -D, the ELISA signals obtained when utilizing the new bio-immunoassay were higher 214 compared to the signal obtained with the AHLC assay. Moreover, applying the new bio-215 immunoassay on AHLC (-) serum (no detected ADA with the AHLC assay) detected relatively high 216 levels of ADA. These results indicated that not all ADA were detected with the AHLC assay as this 217 assay is based on the detection of ADA that comprise the  light chain only. 218 Next, sera from 55 patients treated with IFX were collected at the Chaim Sheba Medical Center 219 and tested for drug levels and ADA using the AHLC assay. The established cohort showed very 220 low drug trough levels and based on the AHLC results, sera were stratified into two groups: 26 221 serum samples were identified as AHLC (-) and 29 as AHLC (+) . Using our newly developed 222 quantitative bio-immunoassay, we found that ADA levels in tested sera ranged between 2.7 to 223 1068.5 g/ml. Serum ADA levels using AHLC compared to the new bio-immunoassay are 224 summarized in Table S1 . More importantly, the new bio-immunoassay demonstrated improved 225 sensitivity compared to AHLC assay manifested in the detection of higher concentrations of ADA 226 in 40 out of the 55 serum samples of which 12 were from the 26 AHLC (-) samples. 227
228
Neutralization index of ADA 229
Due to high clinical relevance and different mechanism of action of bADA and ntADA, identifying 230 their relative abundances in serum can provide invaluable insights regarding the nature of the 231 immune response following mAb administration. We modified our newly developed mAb-F(ab')2 232 based bio-immunoassay by blocking the coated IFX-F(ab')2 binding site with TNFα in order to 233 obtain a differential signal compared to the unblocked assay ( Figure 3A) . In order to block the 234 binding site of IFX-F(ab')2 towards TNFα and prevent the binding of anti-idiotypic ADA (i.e. 235 ntADA) to the drug, recombinant human TNFα (rhTNFα) fused to a His-tag was cloned and 236 expressed (see materials and methods). In-house production of rhTNFα was essential, as the N 237
terminal His-tag was used for monitoring the presence of the rhTNFα throughout the bio-238 immunoassay. 239 240 First, we evaluated the ability of rhTNFα to inhibit the binding of ADA to the coated IFX-F(ab')2 241 by setting up a competitive ELISA where a series of ADA standard concentrations were incubated 242 with a fixed concentration (5nM) of rhTNFα. We monitored the presence of rhTNFα using an HRP-243 conjugated anti-His tag antibody and observed that an increase in ADA concentrations inhibits the 244 binding of rhTNFα to the coated IFX-F(ab')2 (Fig. S3) . 245 246 These data show a competitive effect between the ADA standard and the rhTNFα thus, to ensure 247 that the active site of the IFX-F(ab')2 is occupied throughout the bio-immunoassay, all steps were 248 carried out while maintaining saturating concentrations of rhTNFα (200nM) which is above the 249 maximum concentration of ADA standard applied in the assay. 250
In practice, IFX-F(ab')2 binding site was blocked with rhTNFα by prior incubation of serum with 251 the coated IFX-F(ab')2 hence, the differential signal w/ and w/o the presence of rhTNFα reflects the 252 neutralization capacity (hereby named neutralization index) of the ADA in the tested serum. Using 253 this assay, we evaluated the neutralization index of the 55 sera from patients treated with IFX and 254 7 sera from patients treated with ADL. In sera from patients treated with IFX, we noticed that there 255 are two main neutralization index patterns: those with high differential signal (Fig. 3B ) and low 256 differential signal (Fig. 3C) . All sera from patients treated with ADL were shown to have high 257 neutralization indexes (Fig. S4 ). More interestingly, we found that patients that were stratified as 258
AHLC
(+) have a significantly higher neutralization index compared to those that belong to the 259 AHLC (-) group (Fig. 3D ). This suggests that there is a preferential usage of the  light chain in 260 ntADA as the AHLC (+) group is a priori defined by the presence of chain ADA with  light chains. 261
262
Flow cytometry of B cells following mAb administration 263
To further investigate the molecular landscape of ADA we explored the dynamics of the B cell 264 response following mAb administration. When investigating well-controlled clinical scenarios such 265 as samples from post-vaccination individuals, it is convenient to isolate the antigen-specific B cell 266 as they peak at a well-defined time window (31-33). However, the characteristics of the humoral 267 response and ADA encoding B cell dynamics following mAb administration is unknown. Our 268 working hypothesis postulated that the immune response following mAb administration is a 269 vaccine-like response thus, we expected to observe a wave of PB and mBC peaking several days 270 post mAb infusion. To confirm this, we collected blood samples from a patient that was found to 271 exhibit ADA (20.22µg/ml at D0, 32.33µg/ml at D10) at two time points: prior to IFX infusion (D0) 272 and 10 days post IFX infusion (D10). Total peripheral blood mononuclear cells (PBMCs) were 273 analyzed by FACS and the frequency of B cell subsets were determined. We identified a substantial 274 increase in the frequency of PB and mBC at D10, suggesting that the B cell dynamics following 275 IFX infusion exhibits vaccine-like characteristics in accordance with our working hypothesis (Table  276 S2, Fig. S5 ). non-templated diversification mechanisms that generates the CDRH3, it is considered the most 293 diverse determinant in terms of length and sequence and pivotal for antibody specificity hence, is 294 the focus of our repertoire analysis. 295
Isolating antigen-specific B cells at steady state is challenging as the frequency of these cells in the 296 circulation is very low. However, once the immune system is challenged with an antigen, the wave 297 of PB and mBC is dominated by antigen-specific B cells (31, 32, 37). Based on this, a major fraction 298 of B cells at D10 post mAb infusion should comprise B cell clones responding to the current antigen 299 challenge. Thus, the repertoire of B cells at two time points (pre-and post-infusion) will underline 300 the overall differences in the ongoing ADA encoding B cell response. 301 302 PBs (CD3 -CD19 + CD20 -CD27 + CD38 high ) and mBCs (CD3 -CD19 + CD20 + CD27 + ) were collected 303 using FACS followed by total RNA isolation. The recovered RNA was used as the template for 304 first-strand cDNA synthesis, followed by PCR amplification steps to produce barcoded amplicons 305 of the variable regions of the antibody heavy,  and  light chains (VH, V and V, respectively) as 306 described previously (38). While NGS of antibodies is a powerful tool for immune repertoire 307
analysis, relatively high rates of errors accumulate during the experimental procedure. The V(D)J family usage showed no marked difference between the two time points, B cell subsets 326 and isotypes. The frequency of V-gene family usage was also found to have similar frequency 327 profile as previously described (39, 40). For example, the V gene  light family frequency showed 328 that the V3, V4 and V1 have the most prevalent representation followed by V2, V5 and V6 that had 329 significantly lower frequencies ( and non-synonymous (Fig. S8) . 357
Proteomic analysis of ADA 358
Analysis of serum antibodies provides a comprehensive profile of the humoral immune response 359 and is complementary to the genetic analysis derived from NGS of antibody encoding B cell. 360
Applying an approach that integrates NGS and tandem mass spectrometry (LC-MS/MS) has beenshown to provide invaluable data regarding the composition of antigen-specific serum antibodies 362 and their relationship to B cells and generates new insights regarding the development of the 363 humoral immune response in disease (45) and following vaccination (31, 32). Here we utilized the 364 previously developed omics approach (41, 46) to elucidate the serum ADA composition following 365 IFX infusion. ADA from 10 ml of serum collected at D0 and D10 were subjected to protein G 366 affinity chromatography and total of 9 mg of recovered IgG was digested by IdeS to remove the Fc 367 regions that may mask the MS/MS signal obtained from low abundant peptides. Following 5 hours 368 of digestion, the reaction mixture was subjected to custom made affinity column where the IFX-369 F(ab')2 was coupled to agarose beads and served as the antigen to isolate ADA. Recovered 48.57µg 370 polyclonal ADA-F(ab')2 (IFX-F(ab')2-specific IgG's) in the elution fraction and total F(ab')2 371 (depleted from ADA-F(ab')2) in the flow through fraction were digested with trypsin and injected 372 to high-resolution tandem mass spectrometer analyzer in triplicates. LC-MS/MS raw data files were 373 analyzed using MaxQuant using label free quantitation mode (LFQ) and searched against the 374 custom antibody V gene database derived from the NGS data of B cells isolated from the same 375 donor. Identified peptide from the interpretation of the proteomic spectra were stratified into three 376 types of peptides: informative peptides (iPeptide) that map uniquely to one antibody clonotype in a 377 region that is upstream to the CDRH3, non-informative CDRH3 peptides (niCDRH3) that map to 378 the CDRH3 region of the antibody but do not map uniquely to a single antibody clonotype and 379 informative CDRH3 peptides (iCDRH3) that map uniquely to a single antibody clonotype. 380
Summary of identified peptides in LC-MS/MS are shown in Table S4 . The iCDRH3 peptides 381 enabled the identification of 62 unique ADA CDRH3 clonotypes with 205 associated full-length V 382 gene sequences. The resulting V gene sequences were analyzed to determine their V(D)J family 383 usage and the B cell subset they are mapped to, based on our NGS data (Fig. 5) . 384
The V(D)J family usage of the antibody variable region sequences that were identifies by LC-385 MS/MS (Fig. 5A) showed a similar distribution as observed in the NGS data (Fig. 4A, Fig. S6A ). 386 V family frequency analysis showed that the V1, V3, and V4 are the most dominant V families 387 followed by V2 and V5 that had significantly lower frequencies. D family frequency analysis 388
showed that the D6, D3, D2 and D1 have the most prevalent representation, and J family frequency 389
showed that the J4, J5 and J6 have the most prevalent representation. 390
Next, we examined the distribution of the proteomically identified V gene sequences to B cell 391 subsets ( Fig. 5B) and found that the of V genes predominantly map to mBC from D0 (46.83%), 392 followed by mBC from D10 (27.8%). Moreover, we found that 23.9% of V genes map to D10 PB. 393
Based on the dynamics of antibodies in serum (31), the majority of antibodies produced following 394 a boost challenge are the product of pre-existing mBC cells that were re-activated following drug 395 infusion, much like a response to a vaccine boost (32). 396
As mentioned above, flow cytometry of B cells following IFX administration allowed us to identify 397 a substantial increase in the frequency of PB and mBC at D10, which suggests that the B cell 398 dynamics following IFX infusion exhibits vaccine-like characteristics. Therefore, we expected to 399 find a majority of V gene sequences mapping to IgG + B cells that underwent class switch 400 recombination in the germinal center. Surprisingly, the majority of V gene sequences were mapped 401 to IgM + B cells (Fig. 5C ) indicating that the class switch recombination process is impaired. 402
Next, we performed an analysis of the relative abundances of peptides that map to either the  403 and/or  light chain constant regions. Here, we aimed to provide support to the observation that 404 ntADA preferably use the  light chain. By quantifying the accumulative intensities of peptides 405 derived from the constant region of both light chains we calculate the change in the ratio between 406 peptide that were derived from the affinity chromatography elution fraction (ADA-specific) and the 407 flow through fraction (non ADA-specific). The expected  ratio of total IgG in serum is 2 (47) previously reported to evaluate the serum ADA levels however, these assays mainly provide 437 qualitative measures assisting physicians in decision making for the appropriate intervention 438 strategy when treating the patients and many (if not all) result in underestimation of the actual ADA 439 levels. Moreover, when one aims to investigate the molecular landscape of ADA, it is imperative 440 to provide quantitative measures, thus we first developed a bio-immunoassay to quantify the ADA 441 levels. The developed bio-immunoassay was based on the F(ab')2 region of the mAb, as it was 442 previously reported that the generated ADA are mostly anti-idiotypic (26). The developed bio-443 immunoassay demonstrated higher sensitivity compared to the AHLC assay used initially to detect 444 ADA, and was able to detect ADA where AHLC assay could not. Leveraging its superior 445 sensitivity, we applyed the developed assay on sera from 55 patients treated with IFX, and found 446 that patients that were stratified as AHLC (+) , showed significantly higher levels of ADA (median 447 148.9g/ml) compared to the AHLC (-) (median 0g/ml). These results support the usage of AHLC 448 in the clinic as overall the patients were stratified correctly and clinical decision making was based 449 on a valid indicative assay. Notwithstanding the applicability of the AHLC assay, the new develop 450 F(ab')2 based bio-immunoassay demonstrated that ADA levels can reach extreme concentration 451 that were not detected using the AHLC assay. 452
The mechanism of action of ADA have great influence on drug efficacy. For example, bADA are 453 most likely to enhance the clearance of the drug while ntADA will prevent the drug to bind to its 454 target. Noteworthy, some patients who develop ADA to IFX present a prolonged remission with 455 maintenance therapy, despite repeated indications of high ADA and low IFX trough levels (25). 456
Hence, there is great importance to differentiate between bADA and ntADA or in other words, there 457 is a need to identify serum with high levels of ntADA that may predict the likelihood of the patient 458 to lose response to the administrated mAb. To achieve this, we further revised our developed bio-459 immunoassay to qualitatively measure the neutralization index of the ADA in the serum of patients 460 treated with IFX. Applying this assay on sera from the 55 patients revealed that AHLC (+) patients 461 exhibit significantly higher neutralization index than those that were stratified as AHLC (-) . HisTrap affinity column (GE Healthcare) that was pre-equilibrated with binding buffer. All affinity 561 purification steps were carried out by connecting the affinity column to a peristaltic pump with flow 562 rate of 1/ml/min. Column was washed with 5 column volumes (CV) of wash buffer (50mM Sodium 563 phosphate, pH 8.0, 300mM NaCl, 10% glycerol, 20mM imidazole) followed by elution of rhTNFα 564 with 5CV of elution buffer (50mM Sodium phosphate, pH 6.0, 300mM NaCl, 10% glycerol, 565 500mM imidazole). Elution was collected in 1ml fractions and were analyzed by 12% SDS-PAGE. 566
Fractions containing clean rhTNFα were merged and dialyzed using Amicon Ultra (Mercury) cutoff 567 3K against PBS (pH 7.4). Dialysis products were analyzed by 12% SDS-PAGE for purity and 568 concentration was measured using Take human H+L HRP conjugated antibody (Jackson) was added to each well (1:5000 ratio in 2% w/v 578 BSA in PBS) and incubated for 1 hour at RT, followed by three washing cycles with PBST. 579
Developing was carried out by adding 50µl of 3,3',5,5'-Tetramethylbenzidine (TMB, Southern 580 Biotech) and reaction was quenched by adding 50µl 0.1M sulfuric acid. Plates were read using the 581 Epoch Microplate Spectrophotometer ELISA plate reader (BioTek Instruments). 582 583
Over expression and purification of IdeS 584
The coding sequence corresponding to amino acid residues 38-339 of S. pyogenes IdeS (numbered 585 from the start of the signal sequence) was sub-cloned into the expression vector pET28b (Novagen). 586
The coding sequencing was sub-cloned at the 3' end of Thioredoxin 6xHis-TEV. The complete 587 construct was sub-cloned as previously described (57) and purification of IdeS was carried out as described for rhTNF with a minor modification as 600 follow: Ides was eluted with imidazole gradient (50, 150, 500mM imidazole ), total of 20ml. 20 601 fractions of 1ml were collected from each elution step and evaluated for their purity using 12% 602 SDS-PAGE. All fractions containing clean IdeS were merged and dialyzed O.N. at 4°C against 4L 603 of PBS (pH 7.4), using SnakeSkin dialysis tubing with 10 kDa cutoff (Thermo Fisher Scientific). 604 Dialysis products were analyzed by 12% SDS-PAGE. 605 606
Production of mAb-F(ab')2 607
Intact clinical grade IFX or ADL (designated here as mAb) were digested using in-house produced 608
IdeS. 10mg of mAb was incubated with 300µg of IdeS in the final volume of 500µl PBS for 2.5 609 hours at 37⁰C, followed by a spike-in of additional 300µg of IdeS to achieve full digestion of the 610 Fc fragments. IdeS inactivation was carried out by adding 0.1M of citric acid pH 3 and incubation 611
for 1 minute at RT followed by the addition of PBS (pH 7.4) to neutralized acidic pH. Next, reaction 612 mixture was applied to a 1 mL HiTrap KappaSelect affinity column (GE Healthcare Life Sciences). 613
All affinity purification steps were carried out by connecting the affinity column to a peristaltic 614 pump with flow rate of 1ml/min. The reaction mixture was recycled three times through the 615 KappaSelect column to maximize the capture of intact mAb and mAb-F(ab')2. KappaSelect column 616 was subsequently washed with 5CV of PBS and eluted with 10CV of 100mM glycine·HCl (pH 617 2.7). Collected 1ml elution fractions were immediately neutralized with 100µl of 1.5M Tris·HCl 618 (pH 8.8). Next, the recovered intact mAb and mAb-F(ab')2 fragments were applied to a custom 619 packed 1ml Protein-G agarose column (GenScript). The reaction mixture was recycled three times 620 through the column, which was subsequently washed with 5CV of PBS and eluted with 10CV of 621 100mM glycine·HCl (pH 2.7). The 10ml elution fraction was immediately neutralized with 1ml of 622 1.5M Tris·HCl (pH 8.8). The recovered 10ml mAb-F(ab')2 fragments were dialyzed overnight at 623 4°C against 4L of PBS (pH 7.4) using SnakeSkin dialysis tubing with 10kDa cutoff (Thermo Fisher 624 Scientific). Recovered mAb-F(ab')2 sample were evaluated for purity by SDS-PAGE and their 625 concentration measured by Take5 (BioTek instruments). 626
To test the functionality of the produced mAb-F(ab')2, 96 ELISA plates (Nunc MaxiSorp™ flat-627 bottom, Thermo Fisher Scientific) were coated with 1µg/ml of rhTNFα in PBS and incubated at 628 4°C O.N. ELISA plates were then washed three times with PBST and blocked with 300µl of 2% 629 w/v BSA in PBS for 1 hour at 37⁰C. Next, 50nM of intact mAb and mAb-F(ab')2 (IFX or ADL) in 630 blocking solution was added to each well in triplicates in a 3 fold dilution series, and plates were 631 incubated at RT for 1 hour. Next, plates were washed three times with PBST with 30 second 632 incubation time at each washing cycle. For detection, HRP conjugated anti-human kappa light chain 633 (Jackson) was added to each well (50μl, 1:5000 ratio in 2% w/v BSA in PBS) and incubated for 1 634 hour at RT, followed by three washing cycles with PBST. Developing was carried out by adding 635 50µl of TMB and reaction was quenched by adding 0.1M sulfuric acid. Plates were read using the 636 Epoch Microplate Spectrophotometer ELISA plate reader. To evaluate the purity of the mAb-637 Fa(b')2 samples (i.e. to make sure there are no traces of intact antibody or Fc fragment in the sample) 638 , 96 ELISA plate (Nunc MaxiSorp™ flat-bottom, Thermo Fisher Scientific) were coated with 639 5µg/ml of intact mAb and mAb-F(ab')2 in PBS and incubated at 4°C O.N. Next, plates were washed 640 three time with PBST and blocked with 300µl 2% w/v BSA in PBS for 1 hour at 37⁰C. Next, plates 641 were washed three times with 300 µl PBST, followed by the incubation with HRP conjugated anti-642 human IgG Fc antibody (Jackson) diluted 1:5000 in PBST. Developing was carried out by adding 643 50µl of TMB and reaction was quenched by adding 0.1M sulfuric acid. Plates were read using the 644 Epoch Microplate Spectrophotometer ELISA plate reader (BioTek Instruments). 645
Generation of ADA standard 647
A pool of 17 ADA to IFX positive sera were collected at Sheba Medical Center, and passed through 648 a 2ml custom packed protein G agarose column (GenScript). The pooled sera was recycled three 649 times over the column, which was subsequently washed with 5CV of PBS and eluted with 10CV 650 of 100mM glycine·HCl (pH 2.7). The 10ml elution fraction was immediately neutralized with 1ml 651 of 1.5M Tris·HCl (pH 8.8). The purified mAbs were immediately passed over a custom made 652 rhTNFα affinity column (NHS-activated agarose beads, Thermo Fisher Scientific) in gravity mode. 653
The purified mAbs were recycled three times over the column, which was subsequently washed 654 with 5CV of PBS and eluted with 10CV of 100mM glycine·HCl (pH 2.7). The 10ml elution fraction 655 was immediately neutralized with 1ml of 1.5M Tris·HCl (pH 8.8). The purified mAbs were 656 dialyzed overnight at 4°C against 4L of PBS (pH 7.4) using SnakeSkin dialysis tubing with 10kDa 657 cutoff (Thermo Fisher Scientific). Purified mAbs were analyzed for purity using 12% SDS-PAGE 658 and concentration was determined by Take3 (BioTek instruments). 659
To test functionality, 96 ELISA plate were coated with 5µg/ml of mAb-F(ab')2 in PBS (pH 7.4) 660 and incubated at 4°C O.N. ELISA plates were then washed three times with PBST and blocked 661 with 300µl of 2% w/v BSA in PBS for 1 hour at 37⁰C. Next, 50nM of the purified ADA in blocking 662 solution were added to each well in triplicates with 3 fold dilution series and plates were incubated 663 at RT for 1 hour. Next, plates were washed three times with PBST with 30 second incubation time 664 at each washing cycle. Next, anti-human Fc HRP conjugate (Jackson) was added to each well at 665 the detection phase (50μl, 1:5000 ratio in 2% w/v BSA in PBS) and incubated for 1 hour at RT, 666 followed by three washing cycles with PBST. Developing was carried out by adding 50µl of TMB 667 and reaction was quenched by adding 0.1M sulfuric acid. Plates were read using the Epoch 668
Microplate Spectrophotometer ELISA plate reader. 669 670
Quantitative measurement of ADA in serum 671
The schematic configuration of the bio-immunoassay for the quantitative measurement of ADA in 672 serum is described in Fig. 2B and was carried out as follows: ELISA plates that were coated 673 overnight at 4°C with 5μg/ml produced IFX-F(ab')2 in PBS (pH 7.4). ELISA plates were then 674 washed three times with PBST and blocked with 300µl of 2% w/v BSA in PBS for 1 hour at 37⁰C. 675
Next, triplicates of 1:400 diluted serum samples were added at triplicates and serially diluted 2 fold 676 in 2% w/v BSA in PBS, 10% horse serum (Biological Industries) and 1% Tween 20 in PBS (1:400-677 1:51,200 serum dilution factor). Plates were incubated for 1 hour at RT. On the same plate, serial 678 dilutions of 10nM ADA standard were incubated in triplicate and serially diluted 2 fold in 2% w/v 679 BSA in PBS, 10% horse serum (Biological Industries) and 1% Tween 20 in PBS, to allow theconversion of the tested serum to units per milliliter. ELISA plates were washed three times with 681 PBST and 50μl of HRP conjugated anti-human IgG Fc was added to each well (50μl, 1:5000 ratio 682 in 2% w/v BSA in PBS) and incubated for 1 hour at RT. ELISA plate was then washed three times 683 with PBST and developed by adding 50µl of TMB followed by quenching with 50l 0.1M sulfuric 684 acid. Plates were read using the Epoch Microplate Spectrophotometer ELISA plate reader. 685 686
Neutralization index of ADA 687
Neutralization capacity was determined using ELISA plates that were coated overnight at 4°C with 688 5μg/ml IFX-F(ab')2 in PBS (pH 7.4 ELISA plates were then washed three times with PBST and 689 blocked with 300µl of 2% w/v BSA in PBS for 1 hr at 37⁰C. Next, triplicates of 1:400 diluted serum 690 samples were added to the negative TNFα wells and serially diluted 2 fold in 2% w/v BSA in PBS, 691 10% horse serum (Biological Industries) and 1% Tween 20 in PBS. Triplicates of 1:400 diluted 692 serum samples with 200nM rhTNFα were also added to the remaining wells and serially diluted 2 693 fold in 2% w/v BSA in PBS, 10% horse serum (Biological Industries) and 1% Tween 20 in PBS 694
(1:400-1:51,200 serum dilution factor). Plates were incubated for 1 hour at RT. ELISA plates were 695 washed three times with PBST and 50μl of HRP conjugated anti-human IgG Fc antibody or anti 696 HRP conjugated His-tag antibody were added at the detection phase (50μl, 1:5000 ratio in 2% w/v 697 BSA in PBS) and incubated for 1 hour at RT, followed by three washing cycles with PBST. 698
Developing was carried out by adding 50µl of TMB and reaction was quenched by adding 0.1M 699 sulfuric acid. Plates were read using the Epoch Microplate Spectrophotometer ELISA plate reader. 700 First-strand cDNA generation was performed with 100ng of isolated total RNA using a SuperScript 731 RT II kit (Invitrogen) and oligo-dT primer, according to manufacturer's protocol. After cDNA 732 synthesis, PCR amplification was performed to amplify the VH and VL genes using a primer set 733 described previously (32) with overhang nucleotides to facilitate Illumina adaptor addition during 734 the second PCR (Table S3) . PCR reactions were carried out using FastStart™ High Fidelity PCR 735 System (Roche) with the following cycling conditions: 95°C denaturation for 3 min; 95°C for 30 736 sec, 50°C for 30 sec, and 68°C for 1 min for four cycles; 95°C for 30 sec, 55°C for 30 sec, and 68°C 737 for 1 min for four cycles; 95°C for 30 sec, 63°C for 30 sec, and 68°C for 1 min for 20 cycles; and 738 a final extension at 68°C for 7 min. PCR products were purified using AMPure XP beads (Beckman 739 Coulter), according to manufacturer's protocol (ratio x 1.8 in favor of the beads). Recovered DNA 740 products from the first PCR was applied to a second PCR amplification to attach Illumina adaptors 741 to the amplified VH and VL genes using the primer extension method as described previously (38). 742 PCR reactions were carried out using FastStart™ High Fidelity PCR System (Roche) with the 743 following cycling conditions: 95°C denaturation for 3 min; 95°C for 30 sec, 40°C for 30 sec, and 744 68°C for 1 min for two cycles; 95°C for 30 sec, 65°C for 30 sec, and 68°C for 1 min for 7 cycles; 745 and a final extension at 68°C for 7 min. PCR products were applied to 1% agarose DNA gel 746 electrophoresis and gel-purified with Zymoclean™ Gel DNA Recovery Kit (Zymo Research) 747 according to the manufacturer's instructions. VH and VL libraries concentration were measured 748 using Qubit system (Thermo Fisher Scientific) and library quality was assessed using the 749 Bioanalyzer 2100 system (Agilent) or the 4200 TapeStation system (Agilent). All VH libraries were 750 produced in duplicates starting with RNA as the common source template. The VL were produced 751 with one replicate. 752 VH and VL libraries from sorted B cell were subjected to NGS on the MiSeq platform with the 753 reagent kit V3 2x300 bp paired-end (Illumina), using an input concentration of 16pM with 5% 754
PhiX. 755
Raw fastq files were processed using our recently reported ASAP webserver (34). ASAP analysis 756 resulted in a unique, full-length VH and VL gene sequences database for each time point. The 757 resultant database was used as a reference database to search the LC-MS/MS spectra. All elution fractions were evaluated for their purity using 12% SDS-PAGE and 11 purified 1 ml 766
IgG fractions were combined and dialyzed overnight at 4°C against 4L of PBS (pH 7.4) using 767
SnakeSkin dialysis tubing with 1 kDa cutoff (Thermo Fisher Scientific). 768
Next, 9mg of total IgG were digested with 100µg of IdeS in the final volume of 2ml PBS for 5 hour 769 at 37⁰C. IdeS inactivation was carried out by adding 0.1M of citric acid pH 3 and incubation for 1 770 minute at RT followed by the addition of PBS (pH 7.4) to neutralize the low pH. Total serum F(ab')2 771 was then applied to a one ml custom made affinity column comprised of IFX-F(ab')2 coupled to 772 NHS-activated agarose beads (Thermo Fisher Scientific). The purified serum F(ab')2 were recycled 773 three times over the affinity column, which was subsequently washed with 5CV of PBS and eluted 774 with 15CV of 100mM glycine·HCl (pH 2.7) and collected into Maxymum Recovery Eppendorf 775 (Axygen Scientific). A total of 30x0.5ml elution fractions and 1x50ml flow-through were 776 immediately neutralized with 50 and 100µl (respectively) of 1.5M Tris·HCl (pH 8.8). The purified 777
antigen-specific F(ab')2 were dialyzed overnight at 4°C against 4L of PBS (pH 7.4) using SnakeSkin 778 dialysis tubing with 10kDa cutoff (Thermo Fisher Scientific). Elution and flow-through fractions 779 were trypsin-digested, and resulting peptides were fractionated and sequenced by nanoflow LC-780 electrospray MS/MS on an Orbitrap Velos Pro hybrid mass spectrometer (Thermo Scientific), in 781 tailed, and a P value less than 0.05 were considered statistically significant. All statistics were 815 performed with GraphPad Prism software (version 7, San Diego, California). 816 817 818 819 The newly developed mAb-F(ab')2 based bio-immunoassay configuration. The assay is based on an ELISA where mAb-F(ab')2 is used as the coating agent followed by differential dilutions of tested sera. anti-Fc HRP conjugate is used at the detection phase. (C) Graph representing the ELISA results obtained utilizing the AHLC assay on two serum sample. This assay enabled the stratification of the tested sera to those that show detectable levels of ADA (AHLC (+) ) and those with no detectable levels of ADA (AHLC (-) ). (D) Both serum samples were applied to the newly developed mAb-F(ab')2 based bio-immunoassay. This assay was able to detect ADA in both sera. For C-D, averages were calculated as mean, with error bars indicating s.d. ) and (C) serum sample with no detectable levels of ADA (AHLC (-) ). (D) Scatter plot consolidating the neutralization index obtained by applying the immunoassay on sera from 55 patients treated with IFX (***P = 0.0003, MannWhitney U test). For B-C, averages were calculated as mean, with error bars indicating s.d. isotypes, based on NGS data.
